|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Schneider F and Dacic S: Histopathologic
and molecular approach to staging of multiple lung nodules. Transl
Lung Cancer Res. 6:540–549. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rudin CM, Brambilla E, Faivre-Finn C and
Sage J: Small-cell lung cancer. Nat Rev Dis Primers.
7(3)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Suresh K, Naidoo J, Lin CT and Danoff S:
Immune checkpoint immunotherapy for non-small cell lung cancer:
Benefits and pulmonary toxicities. Chest. 154:1416–1423.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Law AMK, Valdes-Mora F and Gallego-Ortega
D: Myeloid-derived suppressor cells as a therapeutic target for
cancer. Cells. 9(561)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gabrilovich DI: Myeloid-derived suppressor
cells. Cancer Immunol Res. 5:3–8. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hegde S, Leader AM and Merad M: MDSC:
Markers, development, states, and unaddressed complexity. Immunity.
54:875–884. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Talmadge JE and Gabrilovich DI: History of
myeloid-derived suppressor cells. Nat Rev Cancer. 13:739–752.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cassetta L, Baekkevold ES, Brandau S,
Bujko A, Cassatella MA, Dorhoi A, Krieg C, Lin A, Loré K, Marini O,
et al: Deciphering myeloid-derived suppressor cells: Isolation and
markers in humans, mice and non-human primates. Cancer Immunol
Immunother. 68:687–697. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tao J, Han D, Gao S, Zhang W, Yu H, Liu P,
Fu R, Li L and Shao Z: CD8+ T cells exhaustion induced
by myeloid-derived suppressor cells in myelodysplastic syndromes
patients might be through TIM3/Gal-9 pathway. J Cell Mol Med.
24:1046–1058. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Condamine T and Gabrilovich DI: Molecular
mechanisms regulating myeloid-derived suppressor cell
differentiation and function. Trends Immunol. 32:19–25.
2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chang AL, Miska J, Wainwright DA, Dey M,
Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, et al:
CCL2 produced by the glioma microenvironment is essential for the
recruitment of regulatory T cells and myeloid-derived suppressor
cells. Cancer Res. 76:5671–5682. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Togashi Y, Shitara K and Nishikawa H:
Regulatory T cells in cancer immunosuppression-implications for
anticancer therapy. Nat Rev Clin Oncol. 16:356–371. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Adair PR, Kim YC, Zhang AH, Yoon J and
Scott DW: Human tregs made antigen specific by gene modification:
The power to treat autoimmunity and antidrug antibodies with
precision. Front Immunol. 8(1117)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ohue Y and Nishikawa H: Regulatory T
(Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Cancer Sci. 110:2080–2089. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Park HJ, Park JS, Jeong YH, Son J, Ban YH,
Lee BH, Chen L, Chang J, Chung DH, Choi I and Ha SJ: PD-1
upregulated on regulatory T cells during chronic virus infection
enhances the suppression of CD8+ T cell immune response via the
interaction with PD-L1 expressed on CD8+ T cells. J Immunol.
194:5801–5811. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lee-Chang C, Rashidi A, Miska J, Zhang P,
Pituch KC, Hou D, Xiao T, Fischietti M, Kang SJ, Appin CL, et al:
Myeloid-derived suppressive cells promote B cell-mediated
immunosuppression via transfer of PD-L1 in glioblastoma. Cancer
Immunol Res. 7:1928–1943. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cai J, Wang D, Zhang G and Guo X: The role
Of PD-1/PD-L1 axis in Treg development and function: implications
for cancer immunotherapy. Onco Targets Ther. 12:8437–8445.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lababede O, Meziane M and Rice T: Seventh
edition of the cancer staging manual and stage grouping of lung
cancer: Quick reference chart and diagrams. Chest. 139:183–189.
2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Scrimini S, Pons J, Agustí A, Soriano JB,
Cosio BG, Torrecilla JA, Núñez B, Córdova R, Iglesias A, Jahn A, et
al: Differential effects of smoking and COPD upon circulating
myeloid derived suppressor cells. Respir Med. 107:1895–1903.
2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Schrijver IT, Théroude C and Roger T:
Myeloid-derived suppressor cells in sepsis. Front Immunol.
10(327)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Salminen A, Kauppinen A and Kaarniranta K:
Myeloid-derived suppressor cells (MDSC): An important partner in
cellular/tissue senescence. Biogerontology. 19:325–339.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sivagnanalingam U, Beatty PL and Finn OJ:
Myeloid derived suppressor cells in cancer, premalignancy and
inflammation: A roadmap to cancer immunoprevention. Mol Carcinog.
59:852–861. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vignali DAA, Collison LW and Workman CJ:
How regulatory T cells work. Nat Rev Immunol. 8:523–532.
2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Marshall EA, Ng KW, Kung SH, Conway EM,
Martinez VD, Halvorsen EC, Rowbotham DA, Vucic EA, Plumb AW,
Becker-Santos DD, et al: Emerging roles of T helper 17 and
regulatory T cells in lung cancer progression and metastasis. Mol
Cancer. 15(67)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Plitas G, Konopacki C, Wu K, Bos PD,
Morrow M, Putintseva EV, Chudakov DM and Rudensky AY: Regulatory T
cells exhibit distinct features in human breast cancer. Immunity.
45:1122–1134. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Toker A, Nguyen LT, Stone SC, Yang SYC,
Katz SR, Shaw PA, Clarke BA, Ghazarian D, Al-Habeeb A, Easson A, et
al: Regulatory T cells in ovarian cancer are characterized by a
highly activated phenotype distinct from that in melanoma. Clin
Cancer Res. 24:5685–5696. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Erlandsson A, Carlsson J, Lundholm M, Fält
A, Andersson SO, Andrén O and Davidsson S: M2 macrophages and
regulatory T cells in lethal prostate cancer. Prostate. 79:363–369.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kumagai S, Togashi Y, Kamada T, Sugiyama
E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y,
Matsui S, et al: The PD-1 expression balance between effector and
regulatory T cells predicts the clinical efficacy of PD-1 blockade
therapies. Nat Immunol. 21:1346–1358. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY,
Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, et al: Stromal
PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T
cells define the response of different subsets of non-small cell
lung cancer to PD-1/PD-L1 blockade immunotherapy. J Thorac Oncol.
13:521–532. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gattinoni L, Ranganathan A, Surman DR,
Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA and
Restifo NP: CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell
function is CD4+ T-cell dependent. Blood. 108:3818–3823.
2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lang C, Wang J and Chen L: CD25-expressing
Th17 cells mediate CD8+ T cell suppression in CTLA-4
dependent mechanisms in pancreatic ductal adenocarcinoma. Exp Cell
Res. 360:384–389. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Walker LSK: Treg and CTLA-4: Two
intertwining pathways to immune tolerance. J Autoimmun. 45:49–57.
2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Krummey SM and Ford ML: Braking bad: Novel
mechanisms of CTLA-4 inhibition of T cell responses. Am J
Transplant. 14:2685–2690. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chae YK, Arya A, Iams W, Cruz MR, Chandra
S, Choi J and Giles F: Current landscape and future of dual
anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons
learned from clinical trials with melanoma and non-small cell lung
cancer (NSCLC). J Immunother Cancer. 6(39)2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Erfani N, Mehrabadi SM, Ghayumi MA,
Haghshenas MR, Mojtahedi Z, Ghaderi A and Amani D: Increase of
regulatory T cells in metastatic stage and CTLA-4 over expression
in lymphocytes of patients with non-small cell lung cancer (NSCLC).
Lung Cancer. 77:306–311. 2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kumar V, Patel S, Tcyganov E and
Gabrilovich DI: The nature of myeloid-derived suppressor cells in
the tumor microenvironment. Trends Immunol. 37:208–220.
2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sinha P, Okoro C, Foell D, Freeze HH,
Ostrand-Rosenberg S and Srikrishna G: Proinflammatory S100 proteins
regulate the accumulation of myeloid-derived suppressor cells. J
Immunol. 181:4666–4675. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Guha P, Gardell J, Darpolor J, Cunetta M,
Lima M, Miller G, Espat NJ, Junghans RP and Katz SC: STAT3
inhibition induces Bax-dependent apoptosis in liver tumor
myeloid-derived suppressor cells. Oncogene. 38:533–548.
2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
amauchi Y, Safi S, Blattner C, Rathinasamy
A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF,
et al: Circulating and tumor myeloid-derived suppressor cells in
resectable non-small cell lung cancer. Am J Respir Crit Care Med.
198:777–787. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Li R, Salehi-Rad R, Crosson W, Momcilovic
M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, et al:
Inhibition of granulocytic myeloid-derived suppressor cells
overcomes resistance to immune checkpoint inhibition in
LKB1-deficient non-small cell lung cancer. Cancer Res.
81:3295–3308. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ouzounova M, Lee E, Piranlioglu R, El
Andaloussi A, Kolhe R, Demirci MF, Marasco D, Asm I, Chadli A,
Hassan KA, et al: Monocytic and granulocytic myeloid derived
suppressor cells differentially regulate spatiotemporal tumour
plasticity during metastatic cascade. Nat Commun.
8(14979)2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790.
2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Lu C, Redd PS, Lee JR, Savage N and Liu K:
The expression profiles and regulation of PD-L1 in tumor-induced
myeloid-derived suppressor cells. Oncoimmunology.
5(e1247135)2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Eckert I, Ribechini E and Lutz MB: In
vitro generation of murine myeloid-derived suppressor cells,
analysis of markers, developmental commitment, and function.
Methods Mol Biol. 2236:99–114. 2021.PubMed/NCBI View Article : Google Scholar
|
